MS
Masahito Suzuki
About Masahito Suzuki
Data last updated:
Masahito Suzuki is a Director at Eisai Pharmaceuticals India Private Limited (since 2025). The company operates in Pharma. Eisai Pharmaceuticals India Private Limited reported revenue of ₹402 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Eisai Pharmaceuticals India Private Limited U21002AP2007PTC053247 | Director | 16 Jun 2025 | 2007 | ₹402 Cr (FY 2025) | Active |
Board colleagues of Masahito Suzuki
| Name | DIN | Company | Designation |
|---|---|---|---|
| Akiko Nakahama | 11141964 | Eisai Pharmaceuticals India Private Limited | Director |
| Girish Dixit | 08591725 | Eisai Pharmaceuticals India Private Limited | Director |
| Kentaro Nagane | 10526897 | Eisai Pharmaceuticals India Private Limited | Director |
| Mitsuru Shomon | 09299363 | Eisai Pharmaceuticals India Private Limited | Director |
| Shohei Kanazawa | 08760183 | Eisai Pharmaceuticals India Private Limited | Director |
| Takuya Kijima | 11343972 | Eisai Pharmaceuticals India Private Limited | Additional Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Masahito Suzuki
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Masahito Suzuki
Masahito Suzuki currently holds 1 directorship: Eisai Pharmaceuticals India Private Limited (Director, since 16 Jun 2025, revenue ₹402 Cr (FY 2025)).
Masahito Suzuki was first appointed on 16 Jun 2025 as Director at Eisai Pharmaceuticals India Private Limited.
The current boards of Masahito Suzuki's companies include Akiko Nakahama (Eisai Pharmaceuticals India Private Limited), Girish Dixit (Eisai Pharmaceuticals India Private Limited), Kentaro Nagane (Eisai Pharmaceuticals India Private Limited), Mitsuru Shomon (Eisai Pharmaceuticals India Private Limited), Shohei Kanazawa (Eisai Pharmaceuticals India Private Limited), Takuya Kijima (Eisai Pharmaceuticals India Private Limited).